VALUE OF NICOTINIC ACID IN THE CURRENT CARDIOLOGY
Statin intake is a standard in the treatment of patients with atherosclerosis nowadays. These drugs therapy associates with 30% risk reduction in mortality and coronary events. However , the threat of recurrent events is sufficiently high in large part of patients. This can be related to low level o...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Stolichnaya Izdatelskaya Kompaniya
2016-01-01
|
Series: | Racionalʹnaâ Farmakoterapiâ v Kardiologii |
Subjects: | |
Online Access: | https://www.rpcardio.com/jour/article/view/811 |
id |
doaj-675fd37f378f49eaa5f47e5c9d41a6c3 |
---|---|
record_format |
Article |
spelling |
doaj-675fd37f378f49eaa5f47e5c9d41a6c32021-09-03T13:15:20ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532016-01-017336537010.20996/1819-6446-2011-7-3-365-370810VALUE OF NICOTINIC ACID IN THE CURRENT CARDIOLOGYE. P. Trukhacheva0M. V. Ezhov1Russian Cardiology Research and Production ComplexRussian Cardiology Research and Production ComplexStatin intake is a standard in the treatment of patients with atherosclerosis nowadays. These drugs therapy associates with 30% risk reduction in mortality and coronary events. However , the threat of recurrent events is sufficiently high in large part of patients. This can be related to low level of high density lipoprotein cholesterol as well as elevated levels of triglycerides and lipoprotein(a). Nicotinic acid intake in these patients may be necessary for the normalization of lipid profile, including lipoprotein(a), and will be able to reduce residual cardiovascular risk. Evidence-based medicine data are presented to prove an efficacy of nicotinic acid in high doses in cardiology practice. Nicotinic acid both in monotherapy and in combination with statins contributes to coronary and carotid atherosclerosis regression and reduces an incidence of cardiovascular complications. Long-acting formulation of nicotinic acid, correct receiving regime and blood bio-chemical monitoring contribute to long-term safety of the drug in patients with clinically significant atherosclerosis.https://www.rpcardio.com/jour/article/view/811nicotinic acidresidual risklipoprotein(a)atherosclerosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
E. P. Trukhacheva M. V. Ezhov |
spellingShingle |
E. P. Trukhacheva M. V. Ezhov VALUE OF NICOTINIC ACID IN THE CURRENT CARDIOLOGY Racionalʹnaâ Farmakoterapiâ v Kardiologii nicotinic acid residual risk lipoprotein(a) atherosclerosis |
author_facet |
E. P. Trukhacheva M. V. Ezhov |
author_sort |
E. P. Trukhacheva |
title |
VALUE OF NICOTINIC ACID IN THE CURRENT CARDIOLOGY |
title_short |
VALUE OF NICOTINIC ACID IN THE CURRENT CARDIOLOGY |
title_full |
VALUE OF NICOTINIC ACID IN THE CURRENT CARDIOLOGY |
title_fullStr |
VALUE OF NICOTINIC ACID IN THE CURRENT CARDIOLOGY |
title_full_unstemmed |
VALUE OF NICOTINIC ACID IN THE CURRENT CARDIOLOGY |
title_sort |
value of nicotinic acid in the current cardiology |
publisher |
Stolichnaya Izdatelskaya Kompaniya |
series |
Racionalʹnaâ Farmakoterapiâ v Kardiologii |
issn |
1819-6446 2225-3653 |
publishDate |
2016-01-01 |
description |
Statin intake is a standard in the treatment of patients with atherosclerosis nowadays. These drugs therapy associates with 30% risk reduction in mortality and coronary events. However , the threat of recurrent events is sufficiently high in large part of patients. This can be related to low level of high density lipoprotein cholesterol as well as elevated levels of triglycerides and lipoprotein(a). Nicotinic acid intake in these patients may be necessary for the normalization of lipid profile, including lipoprotein(a), and will be able to reduce residual cardiovascular risk. Evidence-based medicine data are presented to prove an efficacy of nicotinic acid in high doses in cardiology practice. Nicotinic acid both in monotherapy and in combination with statins contributes to coronary and carotid atherosclerosis regression and reduces an incidence of cardiovascular complications. Long-acting formulation of nicotinic acid, correct receiving regime and blood bio-chemical monitoring contribute to long-term safety of the drug in patients with clinically significant atherosclerosis. |
topic |
nicotinic acid residual risk lipoprotein(a) atherosclerosis |
url |
https://www.rpcardio.com/jour/article/view/811 |
work_keys_str_mv |
AT eptrukhacheva valueofnicotinicacidinthecurrentcardiology AT mvezhov valueofnicotinicacidinthecurrentcardiology |
_version_ |
1717816810120675328 |